These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 8867518

  • 1. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
    Gancher ST, Woodward WR, Nutt JG.
    Clin Neuropharmacol; 1996 Feb; 19(1):59-64. PubMed ID: 8867518
    [Abstract] [Full Text] [Related]

  • 2. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004 Feb; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

  • 3. [Apomorphine in treatment of Parkinson's disease with fluctuations].
    Zaleska B, Domzał T.
    Neurol Neurochir Pol; 1999 Feb; 33(6):1297-303. PubMed ID: 10791032
    [Abstract] [Full Text] [Related]

  • 4. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
    Antonini A, Jost WH.
    Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
    [Abstract] [Full Text] [Related]

  • 5. [Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
    Ferraz HB, Azevedo-Silva SM, Borges V, Rocha MS, Andrade LA.
    Arq Neuropsiquiatr; 1995 Jun; 53(2):245-51. PubMed ID: 7487531
    [Abstract] [Full Text] [Related]

  • 6. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ.
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [Abstract] [Full Text] [Related]

  • 7. Time course of tolerance to apomorphine in parkinsonism.
    Gancher ST, Nutt JG, Woodward WR.
    Clin Pharmacol Ther; 1992 Nov; 52(5):504-10. PubMed ID: 1424425
    [Abstract] [Full Text] [Related]

  • 8. [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].
    Drapier S, Vérin M.
    Rev Neurol (Paris); 2006 Oct; 162(10):1019-23. PubMed ID: 17028572
    [Abstract] [Full Text] [Related]

  • 9. Apomorphine: an underutilized therapy for Parkinson's disease.
    Poewe W, Wenning GK.
    Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
    [Abstract] [Full Text] [Related]

  • 10. Continuous dopaminergic stimulation in Parkinson's disease.
    Obeso JA, Luquin MR, Vaamonde J, Grandas F, Martinez Lage JM.
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922
    [Abstract] [Full Text] [Related]

  • 11. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study.
    Gunzler SA, Koudelka C, Carlson NE, Pavel M, Nutt JG.
    Arch Neurol; 2008 Feb; 65(2):193-8. PubMed ID: 18268187
    [Abstract] [Full Text] [Related]

  • 12. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 13. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T, Van der Geest R, Danhof M.
    Adv Neurol; 1999 Nov; 80():535-44. PubMed ID: 10410768
    [No Abstract] [Full Text] [Related]

  • 14. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ, Sesar-Ignacio Á.
    Rev Neurol; 2012 Nov; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [Abstract] [Full Text] [Related]

  • 15. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC, Burguera JA.
    Rev Neurol; 2012 Nov; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [Abstract] [Full Text] [Related]

  • 16. [Limits of conventional oral and transdermal medication in Parkinson's disease].
    García-Ruiz PJ, Luquin MR.
    Rev Neurol; 2012 Nov; 55 Suppl 1():S3-6. PubMed ID: 23169231
    [Abstract] [Full Text] [Related]

  • 17. [Use of apomorphine in the treatment of Parkinson's disease].
    Pollak P, Gervason CL.
    Presse Med; 1991 Sep 21; 20(29):1361-4. PubMed ID: 1835009
    [No Abstract] [Full Text] [Related]

  • 18. Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine.
    Sigurdardóttir GR, Nilsson C, Odin P, Grabowski M.
    Acta Neurol Scand; 2001 Aug 21; 104(2):92-6. PubMed ID: 11493225
    [Abstract] [Full Text] [Related]

  • 19. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV, Katunina EA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013 Aug 21; 113(12):105-12. PubMed ID: 24596973
    [No Abstract] [Full Text] [Related]

  • 20. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.
    Grandas F, Gancher ST, Rodriguez M, Lera G, Nutt JG, Obeso JA.
    Clin Neuropharmacol; 1992 Feb 21; 15(1):13-8. PubMed ID: 1576595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.